Trident Lifeline share price
BSE: 543616Pharmaceuticals & BiotechnologySmall Cap
Last close ₹407.00up ₹12.75 (3.23%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹394.25.
52-week range of traded prices to 23 Oct 2026
₹229.95Low, 24 Mar 2026₹425.00High, 16 Oct 2026
- Next results date: the board meets on 26 Oct 2026 to consider: half yearly results and interim dividend.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹488 Cr2,106th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 29 Jul 2026
- 23.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 May 2026
- 4.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 Jul 2026
- 25.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 May 2026
- 0.68
- Volume, BSEVolume. Shares traded on the last trading day.
- 10,800
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 29 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹34 Crdown 32.50%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹5.03 Crdown 25.20%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 14.9%
Revenue by year
Peak revenue ₹129 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 11 Nov | Dec 2024 | Mar 2025 | Jun 2025Filed 28 Jul | Sep 2025Filed 14 Nov | Dec 2025Filed 17 Jan | Mar 2026Filed 7 May | Jun 2026Filed 29 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.1 | – | – | 23.6 | 29.8 | 25.7 | 50.0 | 33.7 |
| Net profit | 3.1 | – | – | 3.1 | 4.9 | 4.3 | 6.7 | 5.0 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 19.2% | – | – | 13.0% | 16.6% | 16.7% | 13.5% | 14.9% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. No results on record for the quarters to Dec 2024 and Mar 2025.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICAL, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, EV/EBITDA: a period of the last twelve months does not state its operating profit. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 30% of 641 trading days over the last 3 years.
LowestHighest
Its median28.7Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 59% of 641 trading days over the last 3 years.
LowestHighest
Its median4.7Industry median2.8
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +4.4% | +56.2% | −33.1% | 0.0% |
| 3 years | +19.0% | +45.0% | −17.9% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1 and 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Trident Lifeline in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 WanburyWANBURY | 624 | 11.2 | 4.3 | 8.4 | +3.6% | +30.0% | 54.9% | 23.3% | 0.00% |
 Influx HealthtechINFLUX | 595 | 28.9 | 5.9 | – | – | – | 20.4% | – | 0.00% |
 TranschemTRANSCHEM | 513 | 76.2 | 6.1 | – | −100.0% | +47.5% | 8.3% | −4.9% | 0.00% |
 KRM AyurvedaKRMAYURVED | 508 | – | 4.4 | – | – | – | – | – | 0.00% |
 Haleos LabsHALEOSLABS | 453 | 28.7 | 2.1 | 13.7 | −3.1% | −8.5% | 7.7% | 7.4% | 0.10% |
 Infinium PharmachemINFINIUM | 446 | 36.7 | 3.7 | – | +21.8% | +41.8% | 10.5% | – | 0.00% |
 Albert DavidALBERTDAVD | 436 | 19.3 | 1.1 | 16.1 | +11.4% | +258.5% | 5.8% | 4.1% | 0.65% |
 Jenburkt PharmaceuticalsJENBURPH | 384 | 11.7 | 2.0 | 8.1 | +9.1% | +1.2% | 17.8% | 19.2% | 2.38% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
21 Oct · Board meeting
Meeting on 26 Oct 2026: half yearly results and interim dividend17 Oct · Announcement under Regulation 30 (LODR)-Allotment
16 Oct · Board meeting
Meeting on 16 Oct 2026
Trident Lifeline share price by year
Each calendar year to 2025.Trident Lifeline share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 310.70 | +11.0% | 317.70 | 225.00 |
| 2024 | 280.00 | +48.9% | 334.00 | 147.30 |
| 2023 | 188.00 | +51.6% | 227.50 | 117.50 |
| 2022 | 124.00 | – | 158.75 | 108.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2022 is from its first session, 10 Oct 2022.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 381.00 | 410.00 | 381.00 | 407.00 | 398.44 | 10,800 |
| 22 Oct 2026 | 390.00 | 407.95 | 390.00 | 394.25 | 399.14 | 19,800 |
| 21 Oct 2026 | 425.00 | 425.00 | 382.50 | 387.95 | 391.88 | 13,800 |
| 19 Oct 2026 | 410.00 | 412.25 | 401.00 | 402.00 | 408.64 | 34,800 |
| 16 Oct 2026 | 413.75 | 425.00 | 405.00 | 419.90 | 413.96 | 21,600 |
| 15 Oct 2026 | 399.65 | 416.95 | 399.65 | 413.75 | 412.56 | 44,400 |
| 14 Oct 2026 | 384.00 | 419.00 | 384.00 | 402.25 | 406.80 | 80,400 |
| 13 Oct 2026 | 380.00 | 380.00 | 375.00 | 378.00 | 378.10 | 7,800 |
| 12 Oct 2026 | 385.00 | 385.00 | 370.00 | 381.50 | 381.43 | 22,800 |
| 9 Oct 2026 | 371.50 | 386.90 | 367.55 | 370.00 | 371.38 | 36,000 |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Trident Lifeline Limited
- BSE code
- 543616
- ISIN
- INE0MKA01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 2022
- Face value
- ₹10
- CIN
- L51909GJ2014PLC078227
- Corporate identity number, the registrar of companies' code for it